In terms of current treatment guidelines, while selective KRAS G12C inhibitors continue to be investigated, the standard of care for advanced-stage KRAS-mutant NSCLC in the first line setting includes anti-PD-(L)1 monotherapy for patients with a PD-L1 tumor proportion score (TPS) ≥ 50% or chemoimmunotherapy, with or without bevacizumab, regardless of PD-L1 expression [4]. Here, CD274 is linked to neoplasm.